Brief: Guard Therapeutics Reports Efficacy Of Rmc-035 In Phase 2 (Akita) And Advances Clinical Development Program

Disruptive Pharma AB (publ)

19/09/2023 07:05

Sept 19 (Reuters) - Guard Therapeutics International AB
(publ)  GUARD.ST :
    * GUARD THERAPEUTICS REPORTS ROBUST EFFICACY OF RMC-035 IN
PHASE 2
(AKITA) AND ADVANCES CLINICAL DEVELOPMENT PROGRAM
    * STATISTICALLY SIGNIFICANT AND CLINICALLY RELEVANT
IMPROVEMENT OF
LONG-TERM KIDNEY FUNCTION (COMPARED TO PLACEBO)
    * STATISTICALLY SIGNIFICANT AND CLINICALLY RELEVANT
REDUCTION OF
MAJOR ADVERSE KIDNEY EVENTS (MAKE) ON DAY 90, I.E. PRIMARY
ENDPOINT IN A FUTURE REGISTRATIONAL PHASE 3 STUDY AS REQUIRED BY
REGULATORY AGENCIES

Source text for Eikon:  ID:nMFN2H8nfd 
Further company coverage:  GUARD.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))